Brief: Calliditas Therapeutics: China CDE/NMPA Recommends Priority Review for Nefecon
30/12/2022 07:34
Dec 30 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CHINA CDE/NMPA RECOMMENDS PRIORITY REVIEW FOR NEFECON FOR
THE
TREATMENT OF PRIMARY IGA NEPHROPATHY
Source text for Eikon: ID:nWkr6PKyxc
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations